Kiora Pharmaceuticals, Inc. - Common Stock (KPRX)

Phoenix, Arizona and New York, New York--(Newsfile Corp. - September 30, 2024) - Lytham...

Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and...

Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be...

Topline Phase I/II First-in-Human Results Presented at AAO 2023Significant improvement in visual field, in concordance with trended improvements in visual...

Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) traded today at a new 52-week high of $6.65. Approximately 147,000 shares have changed hands today, as compared to an average 30-day volume of 19 million shares.

Encinitas, California--(Newsfile Corp. - August 22, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotechnology company developing novel therapies...

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Dallas, Texas--(Newsfile Corp. - December 14, 2022) - Stonegate Healthcare has published a new...

Dallas, Texas--(Newsfile Corp. - September 28, 2022) - Stonegate Capital Partners will host a...

San Diego, CA -- (SBWIRE) -- 02/15/2022 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares over potential securities laws violations by Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.

San Diego, CA -- (SBWIRE) -- 12/15/2021 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares over potential securities laws violations by Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.

San Diego, CA -- (SBWIRE) -- 12/01/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc. .